A review of etoposide in patients with non-small-cell lung cancer (NSCLC)
- 30 June 1982
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 9, 115-118
- https://doi.org/10.1016/s0305-7372(82)80090-x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group BCancer, 1980
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- Chemotherapy of small cell carcinoma of the lung with V. P. 16–213Cancer, 1978
- Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cellsBiochemistry, 1976
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973
- Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxinJournal of Medicinal Chemistry, 1971